Evaluation of Bleb Morphology and Reduction in IOP and Glaucoma Medication following Implantation of a Novel Gel Stent

Table 7

Safety parameters.

	BCVA	MD	CD	SD	CV	6A
Baseline	6.38 ± 3.23	−12.5 ± 8.69	2038.3 ± 724.3	226.1 ± 92.8	40.0 ± 5.4	54.56 ± 8.93
1st week	6.29 ± 2.77	—	—	—	—	—
1st month	6.29 ± 2.83	—	2008.89 ± 568.52	209.11 ± 77.78	39 ± 8.46	56.67 ± 9.22
3rd month	6.38 ± 3.08	—	1798.82 ± 686.77	283.36 ± 160.05	41.45 ± 9.23	53.09 ± 7.79
6th month	6.38 ± 3.08	−12.3 ± 8.61	1859.27 ± 732.67	210 ± 111.35	32.36 ± 6.54	61.73 ± 6.17
1 year	7 ± 2.11	−12.47 ± 8.63	2111.56 ± 443.89	167.56 ± 27.46	34.56 ± 4.45	63.22 ± 6.24

BCVA: best corrected visual acuity; CD: cell endothelial density; SD: standard deviation; CV: coefficient of variation; 6A: cell hexagonality; MD: mean deviation at visual field test.